Citation tools
"The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy." Journal of Nuclear Medicine
64.8
(2023):
1252-1258.
Web. 29 May. 2025.